News

Fourth FDA approval for Vertex's cystic fibrosis medicines The FDA has approved Trikafta™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of…..

New version of SOPHiA Whole Exome Solution to accelerate rare disease characterization SOPHiA GENETICS, a leader in Data-Driven Medicine, has announced  at the American Society of Human Genetics Annual Meeting (ASHG) the release of the new version of its SOPHiA Whole Exome Solution. This advanced genomic application is reducing the…..

$50 million in first close of new advanced therapies fund 4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector,  has completed the first close of its second venture fund, 4BIO Ventures II. Over $50 million of capital has been committed from family offices and institutional…..

The 2018 Nobel Prize in Physiology or Medicine has been jointly awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.  During the 1990s, in his laboratory at the University of California, Berkeley, James P. Allison studied the T-cell protein CTLA-4.…..

A l’occasion de la 7ème journée de la recherche clinique, l’AFCROs, qui regroupe 75 sociétés-membres représentant environ 70% de l’activité dans le domaine de la recherche clinique et épidémiologique, a présenté les chiffres clés de la recherche clinique en France. Cet outil réalisé par les groupes de travail de l’association…..

L’AFCROs, qui regroupe plus de 70 entreprises de la recherche clinique, organise sa 7ème Journée de la Recherche Clinique le 30 janvier 2018 à Paris. La manifestation est ouverte aux institutionnels, aux académiques, aux industriels des produits de santé, de la cosmétique et la nutrition, aux CROs, aux patients et…..